Loading
A phase 1/2 trial of Rilvegostomig in non-small-cell lung cancer, run by AstraZeneca, active and no longer recruiting.
A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC is a phase 1/2 interventional study registered as NCT04995523 by AstraZeneca, with 212 participants enrolled, started 2021-09-14 and due to reach its primary completion in 2026-08-28. Interventions recorded: AZD2936.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Rilvegostomig, AstraZeneca, Non-small-cell lung cancer and the tag pipeline.
Shares Rilvegostomig, AstraZeneca and the tag pipeline.
Shares Rilvegostomig, AstraZeneca and the tag pipeline.
Shares AstraZeneca, Non-small-cell lung cancer and the tag pipeline.
Shares AstraZeneca, Non-small-cell lung cancer and the tag pipeline.
Shares Rilvegostomig, AstraZeneca and the tag pipeline.
Shares Rilvegostomig, AstraZeneca and the tag pipeline.
Shares AstraZeneca, Non-small-cell lung cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/